Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 168171 | 3.74 |
09:34 ET | 45322 | 3.76 |
09:36 ET | 9610 | 3.755 |
09:38 ET | 22189 | 3.73 |
09:39 ET | 12974 | 3.725 |
09:41 ET | 15872 | 3.745 |
09:43 ET | 67284 | 3.7312 |
09:45 ET | 55976 | 3.76 |
09:48 ET | 38772 | 3.785 |
09:50 ET | 28318 | 3.7643 |
09:52 ET | 29930 | 3.775 |
09:54 ET | 61770 | 3.77 |
09:56 ET | 15871 | 3.755 |
09:57 ET | 12533 | 3.76 |
09:59 ET | 10014 | 3.751 |
10:01 ET | 12956 | 3.755 |
10:03 ET | 171262 | 3.755 |
10:06 ET | 43358 | 3.745 |
10:08 ET | 24800 | 3.749 |
10:10 ET | 16625 | 3.745 |
10:12 ET | 54575 | 3.715 |
10:14 ET | 8864 | 3.72 |
10:15 ET | 56981 | 3.715 |
10:17 ET | 71628 | 3.75 |
10:19 ET | 4911 | 3.755 |
10:21 ET | 108670 | 3.765 |
10:24 ET | 1133 | 3.76 |
10:26 ET | 1750 | 3.76 |
10:28 ET | 12645 | 3.765 |
10:30 ET | 44837 | 3.755 |
10:32 ET | 10281 | 3.755 |
10:33 ET | 12059 | 3.765 |
10:35 ET | 1280 | 3.765 |
10:37 ET | 43452 | 3.775 |
10:39 ET | 24424 | 3.78 |
10:42 ET | 561852 | 3.805 |
10:44 ET | 7715 | 3.795 |
10:46 ET | 123466 | 3.785 |
10:48 ET | 2644 | 3.79 |
10:50 ET | 116995 | 3.8 |
10:51 ET | 2509 | 3.79 |
10:53 ET | 13095 | 3.78 |
10:55 ET | 16188 | 3.78 |
10:57 ET | 51073 | 3.785 |
11:00 ET | 15156 | 3.78 |
11:02 ET | 11827 | 3.79 |
11:04 ET | 1603 | 3.79 |
11:06 ET | 5280 | 3.795 |
11:08 ET | 59736 | 3.785 |
11:09 ET | 38641 | 3.77 |
11:11 ET | 13664 | 3.765 |
11:13 ET | 2531 | 3.765 |
11:15 ET | 16481 | 3.775 |
11:18 ET | 38836 | 3.755 |
11:20 ET | 5971 | 3.75 |
11:22 ET | 12669 | 3.755 |
11:24 ET | 4357 | 3.755 |
11:26 ET | 40973 | 3.77 |
11:27 ET | 11024 | 3.765 |
11:29 ET | 5623 | 3.765 |
11:31 ET | 4400 | 3.765 |
11:33 ET | 4201 | 3.765 |
11:36 ET | 23828 | 3.775 |
11:38 ET | 5638 | 3.78 |
11:40 ET | 17609 | 3.76 |
11:42 ET | 1360 | 3.76 |
11:44 ET | 7401 | 3.76 |
11:45 ET | 10682 | 3.755 |
11:47 ET | 2008 | 3.755 |
11:49 ET | 30905 | 3.755 |
11:51 ET | 14497 | 3.755 |
11:54 ET | 4600 | 3.755 |
11:56 ET | 13187 | 3.755 |
11:58 ET | 3231 | 3.755 |
12:00 ET | 4939 | 3.755 |
12:02 ET | 2489 | 3.75 |
12:03 ET | 1662 | 3.75 |
12:05 ET | 2642 | 3.75 |
12:07 ET | 4436 | 3.755 |
12:09 ET | 2022 | 3.755 |
12:12 ET | 8357 | 3.755 |
12:14 ET | 20368 | 3.755 |
12:16 ET | 1768 | 3.755 |
12:18 ET | 2286 | 3.76 |
12:20 ET | 3642 | 3.755 |
12:21 ET | 9116 | 3.76 |
12:23 ET | 1300 | 3.755 |
12:25 ET | 1802 | 3.755 |
12:27 ET | 3662 | 3.755 |
12:30 ET | 4792 | 3.755 |
12:32 ET | 4324 | 3.75 |
12:34 ET | 2598 | 3.75 |
12:36 ET | 5742 | 3.75 |
12:38 ET | 6925 | 3.755 |
12:39 ET | 15038 | 3.75 |
12:41 ET | 5115 | 3.755 |
12:43 ET | 2300 | 3.75 |
12:45 ET | 39166 | 3.77 |
12:48 ET | 5079 | 3.77 |
12:50 ET | 17570 | 3.77 |
12:52 ET | 8772 | 3.775 |
12:54 ET | 1500 | 3.775 |
12:56 ET | 4161 | 3.775 |
12:57 ET | 5124 | 3.77 |
12:59 ET | 18465 | 3.76 |
01:01 ET | 4642 | 3.76 |
01:03 ET | 3469 | 3.76 |
01:06 ET | 2918 | 3.76 |
01:08 ET | 3200 | 3.765 |
01:10 ET | 199181 | 3.76 |
01:12 ET | 22704 | 3.78 |
01:14 ET | 4151 | 3.775 |
01:15 ET | 3100 | 3.78 |
01:17 ET | 5670 | 3.77 |
01:19 ET | 2900 | 3.775 |
01:21 ET | 15511 | 3.77 |
01:24 ET | 78893 | 3.775 |
01:26 ET | 81352 | 3.765 |
01:28 ET | 18595 | 3.765 |
01:30 ET | 10089 | 3.78 |
01:32 ET | 1222 | 3.775 |
01:33 ET | 4009 | 3.77 |
01:35 ET | 4295 | 3.775 |
01:37 ET | 14750 | 3.775 |
01:39 ET | 18209 | 3.79 |
01:42 ET | 2528 | 3.785 |
01:44 ET | 10728 | 3.785 |
01:46 ET | 3467 | 3.78 |
01:48 ET | 232490 | 3.7919 |
01:50 ET | 77412 | 3.77 |
01:51 ET | 676 | 3.775 |
01:53 ET | 8764 | 3.765 |
01:55 ET | 1150 | 3.765 |
01:57 ET | 43133 | 3.775 |
02:00 ET | 11021 | 3.765 |
02:02 ET | 1513 | 3.76 |
02:04 ET | 3579 | 3.765 |
02:06 ET | 1168 | 3.76 |
02:08 ET | 700 | 3.76 |
02:09 ET | 4065 | 3.765 |
02:11 ET | 2338 | 3.765 |
02:13 ET | 6760 | 3.765 |
02:15 ET | 52930 | 3.78 |
02:18 ET | 3281 | 3.775 |
02:20 ET | 7470 | 3.775 |
02:22 ET | 1758 | 3.775 |
02:24 ET | 32394 | 3.77 |
02:26 ET | 1270 | 3.775 |
02:27 ET | 25010 | 3.76 |
02:29 ET | 1060 | 3.77 |
02:31 ET | 1317 | 3.765 |
02:33 ET | 108398 | 3.785 |
02:36 ET | 5325 | 3.78 |
02:38 ET | 600 | 3.785 |
02:40 ET | 1100 | 3.785 |
02:42 ET | 1246 | 3.785 |
02:44 ET | 2934 | 3.785 |
02:45 ET | 88112 | 3.805 |
02:47 ET | 41086 | 3.82 |
02:49 ET | 4584 | 3.82 |
02:51 ET | 19668 | 3.8013 |
02:54 ET | 10938 | 3.81 |
02:56 ET | 65435 | 3.8299 |
02:58 ET | 13904 | 3.825 |
03:00 ET | 8376 | 3.825 |
03:02 ET | 26782 | 3.818 |
03:03 ET | 27702 | 3.825 |
03:05 ET | 1400 | 3.825 |
03:07 ET | 1433 | 3.83 |
03:09 ET | 3551 | 3.83 |
03:12 ET | 2887 | 3.825 |
03:14 ET | 6848 | 3.825 |
03:16 ET | 57867 | 3.835 |
03:18 ET | 68131 | 3.8498 |
03:20 ET | 20727 | 3.845 |
03:21 ET | 17762 | 3.8428 |
03:23 ET | 52045 | 3.86 |
03:25 ET | 69583 | 3.8499 |
03:27 ET | 12487 | 3.845 |
03:30 ET | 6200 | 3.845 |
03:32 ET | 70422 | 3.865 |
03:34 ET | 15597 | 3.865 |
03:36 ET | 21570 | 3.865 |
03:38 ET | 97686 | 3.87 |
03:39 ET | 35135 | 3.875 |
03:41 ET | 48168 | 3.89 |
03:43 ET | 21263 | 3.885 |
03:45 ET | 77863 | 3.89 |
03:48 ET | 8811 | 3.89 |
03:50 ET | 73534 | 3.8975 |
03:52 ET | 66170 | 3.9 |
03:54 ET | 90760 | 3.905 |
03:56 ET | 145984 | 3.905 |
03:57 ET | 101850 | 3.9 |
03:59 ET | 142865 | 3.9 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.2B | -11.3x | --- |
Vera Therapeutics Inc | 2.2B | -20.9x | --- |
Rocket Pharmaceuticals Inc | 2.1B | -8.3x | --- |
Keros Therapeutics Inc | 1.9B | -10.6x | --- |
Dyne Therapeutics Inc | 2.5B | -7.4x | --- |
Sana Biotechnology Inc | 1.9B | -6.1x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -11.3x |
Price/Sales (TTM) | 4,197.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.